ImStem Biotechnology
AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple...
IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX Therapeutics.
